蒙草生態(300355.SZ):公司草種業專利技術數量位居全球草種業創新主體企業排名第四
格隆匯6月11日丨蒙草生態(300355.SZ)在投資者互動平臺表示,公司多年來專注草業科技研發,公司草種業專利技術數量位居全球草種業創新主體企業排名第四。“混合草走路坪及其建造方法” 2022年獲世界知識產權組織頒發的國際發明金獎。公司成功實施了西安奧體中心、鳥巢國家體育場附場、國家北方足球訓練基地、呼和浩特體育場、寧夏足球訓練基地、和林格爾足球小鎮等29塊國內知名球場。完成5000多個草坪停車位和多個走路草坪、休閒綠地項目。形成了“研發-生產-施工-養護”全產業鏈服務能力。公司將持續發揮生態與草種技術優勢,拓展體育場地生態化建設市場,作爲公司“生態+”戰略的重要組成部分。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.